ALLMedicine™ Anaplastic Oligodendroglioma Center

Oct 4th, 2022 - The purpose of this study is to see how effective treatment of high doses of chemotherapy is for your tumor. We will also be looking at the side effects and risks of this treatment. You will receive very high doses of chemotherapy. High doses of c...

Jul 30th, 2022 - Major complex cranial defects may be challenging for the reconstructive microsurgeon. Affected patients often present with impaired soft tissues including dura exposure or fistulas. The lacking structural bony support may cause severe neurological...

Jul 23rd, 2022 - To investigate the correlations between mutations in the telomerase reverse transcriptase (TERT) promoter and isocitrate dehydrogenase (IDH) 1 and 2 mutations or 1p/19q deletion in human gliomas. TERT promoter gene and IDH gene mutations in 110 gl...

Apr 4th, 2022 - Patients will be stratified by the molecular and histologic characteristics of their tumor to one of three treatment strata. STRATUM A: Combination Treatment: ribociclib and gemcitabine. Patient Population: Participants with a diagnosis of refract...

Mar 19th, 2022 - 5-Aminolevulinic acid (5-ALA)-enhanced fluorescence-guided resection of high-grade glioma (HGG) using microscopic blue light visualization offers the ability to improve extent of resection (EOR); however, few descriptions of HGG resection performe...

Sep 14th, 2013 - Primary and metastatic tumors of the central nervous system are a heterogeneous group of neoplasms with varied outcomes and management strategies. Recently, improved survival observed in 2 randomized clinical trials established combined chemothera...

Oct 4th, 2022 - The purpose of this study is to see how effective treatment of high doses of chemotherapy is for your tumor. We will also be looking at the side effects and risks of this treatment. You will receive very high doses of chemotherapy. High doses of c...

Apr 4th, 2022 - Patients will be stratified by the molecular and histologic characteristics of their tumor to one of three treatment strata. STRATUM A: Combination Treatment: ribociclib and gemcitabine. Patient Population: Participants with a diagnosis of refract...

Mar 17th, 2022 - PRIMARY OBJECTIVES: I. To evaluate toxicity and estimate the maximum tolerated dose (MTD) of melphalan (intra-arterially [i.a.]) administered in conjunction with carboplatin (i.a.) and etoposide phosphate (intravenously [i.v.]) undergoing BBBD, in...

Apr 8th, 2020 - OBJECTIVES: I. Determine the efficacy of topotecan in patients with recurrent anaplastic oligodendroglioma or anaplastic mixed oligoastrocytoma. II. Determine the qualitative and quantitative toxicity of topotecan in this patient population on thi...

Sep 18th, 2018 - OBJECTIVES: Determine progression-free survival of patients with newly diagnosed anaplastic oligodendroglioma (AO) or mixed oligoastrocytoma (MOA) treated with temozolomide. Determine the response rate in these patients. Assess the quality of life...

Apr 2nd, 2021 - Transcript:Susan C. Pannullo, MD: The patient who has a glioblastoma will often present with neurologic symptoms, as one would expect. These can include headache, progressive neurologic deficit, and seizures. With the progressive neurologic defici...

Apr 2nd, 2021 - Transcript:Daniela Bota, MD: The diagnosis of glioblastoma has changed a lot during the last years. Originally, the diagnosis was made after the tumor was resected by taking pieces of the tissue and looking at it under the microscope. And the 2 ch...

Dec 5th, 2020 - The carcinoembryonic antigen (CEA) vaccinia has been researched for more than 20 years. Investigational Glioma Vaccine Results Promising A novel vaccine based on dendritic cells and peptides proved to be safe and capable of delivering an im...

Dec 5th, 2020 - Martin J. Van Den Bent, MD A study that unfolded over 17 years has established combination chemotherapy after radiotherapy (RT) as a new standard of care for patients with anaplastic oligodendroglial tumors that contain 1p/19q chromosomal co-del...

Dec 5th, 2020 - Andrew L. Pecora, MD Editor-in-Chief Oncology & Biotech News Chief Innovations Officer, Professor, and Vice President of Cancer Services John Theurer Cancer Center at Hackensack University Medical Center I am sure any of ...